Using grape extract in the treatment of diabetes
Biological researchers in our country succeeded in producing a drug to treat diabetes by using the active ingredients in grape plant extract enclosed in medicinal nanocarriers. The drug nanocarrier, made from cyanidin and delphinidine in grapes, has been shown to reduce the effects of diabetes mellitus in mice with the disease and could be used as a new anti-diabetic product in the pharmaceutical industry. Cyanidin and delphinidine are the two major phenolic compounds in grape varieties and have antioxidant properties.
Due to the increasing prevalence of diabetes mellitus in the world and also to the problems related to the control of this disease, research to develop new methods to control the complications of this disease is necessary and is one of the world’s research priorities. In this disease, a variety of proteins in the body are glycated, which leads to changes in the structure of proteins and their biological activity. Therefore, inhibiting the glycation of proteins is essential to prevent the complications of diabetes. Because the two major compounds of phenolic cyanidin and delphinidine in grapes have beneficial properties such as lowering blood cholesterol and protecting the cardiovascular system, which are complications of diabetes mellitus; In this project, researchers studied the effect of these two compounds in grapefruit in free form and nanoliposomes on reducing the complications of diabetes.
According to Dr. Amir Gharib, a faculty member of the Islamic Azad University, Boroujerd Branch, nanoliposomes containing cyanidin and delphinidine were first prepared with the help of fats such as phosphatidylcholine in soy and cholesterol. In the next step, the effects of these compounds in free form and enclosed in nanoliposomes on the glycation reaction of albumin and hemoglobin A were studied in vitro. Finally, after ensuring the efficacy of the nanoliposomes prepared under these conditions, by treating laboratory mice with diabetes, the glycemic response of albumin and hemoglobin A as well as changes in blood glucose, cholesterol, etc. with the help of these compounds in vitro were investigated. Took.
The results of this study showed that cyanidin and delphinidine, especially in the form enclosed in nanoliposomes, are able to prevent the glycation of albumin and hemoglobin A in vitro, and also in the laboratory mice with diabetes, reduce blood glucose, blood cholesterol and albumin and hemoglobin and hemoglobin. Glycated and increase the amount of glycogen stored in the liver and therefore can be used as compounds to reduce the effects of diabetes mellitus.
Dr. Gharib expressed his hope that the product could be introduced as a new anti-diabetic product by conducting additional and clinical trials.
The results of this research conducted by Dr. Amir Gharib, Dr. Zohreh Faezizadeh and Dr. Masoud Goodarzi (faculty members of Boroujerd Branch of Azad University) in Planta Medica Journal (Vol. 79, No. 17, November, 2103, pp. 1599-1604 ) It has been published .
